PatientSpotlight, by PanaceaIntelPatientSpotlight

Topic · Mental Health

Regulatory

Coverage of FDA, EMA, MHRA, NICE, and other regulatory action across the therapy areas we follow - approvals, pathway choices, and the recalibrated bar each new precedent sets. 3 pieces on regulatory in Mental Health, newest first within each collection.

← All topics
FilterAll (32)Oncology (5)Rare Disease (7)Immunology (1)Neurology (14)Cardiometabolic (1)Women's Health (1)Mental Health (3)

Signals

1
SignalApr 26, 2026FDA · peer-reviewed · industry-filing

Psychedelic-assisted therapy: clinical pipeline progress, regulatory caution

MDMA- and psilocybin-based therapies have advanced through late-stage trials, but the FDA's measured response - and the system requirements those therapies impose on delivery - mean rollout will be slower and more constrained than mechanism enthusiasm suggested.

TreatmentPsychedelicsRegulatoryPipeline

Explained

2
ExplainedApr 26, 2026FDA · peer-reviewed

How pediatric mental health prescribing differs from adult and why it matters

Pediatric mental health prescribing operates under different evidence frameworks, regulatory expectations, and access structures than adult prescribing. Understanding the differences is essential for any sponsor with mental health assets that are eligible for paediatric expansion or that interact with paediatric-eligible populations.

TreatmentDrug developmentRegulatory
ExplainedApr 26, 2026FDA · peer-reviewed · guideline-bodies

How depression staging is being formalised and what that means for trial design

The treatment-resistant depression (TRD) frame has been part of psychiatric research for decades, but the operational definitions have been inconsistent. A more formalised staging system is converging across regulatory, clinical, and trial frames, and the convergence has practical consequences for which patients enroll in which trial and which approvals follow.

DepressionTrdTrial designStaging